C. Stober, MBChB, MRCP, PhD, MSc, Department of Medicine, University of Cambridge, Cambridge, UK.
D.R. Jadon, MBBCh, MRCP, PhD, University of Cambridge, Cambridge, UK.
J Rheumatol Suppl. 2021 Jun;97:4-9. doi: 10.3899/jrheum.201667.
At the 2020 Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)-Collaborative Research Network (CRN) annual meeting, the GRAPPA-CRN group presented a pilot investigator-initiated study protocol to test electronic case report forms (eCRFs) and proposed Standardized Operating Procedures (SOPs) to evaluate biomarkers of psoriatic arthritis (PsA) associated with axial disease. The progress on 3 studies was also presented: BioDAM PsA (Biomarkers as Predictors of structural DAMage in PsA; to validate soluble biomarkers as predictors of structural damage in PsA), PreventPsA (examining the development of PsA and risk factors among patients with psoriasis and no arthritis), and PredictORPsA (Predicting Treatment respOnse in patients with eaRly PsA; in collaboration with Pfizer using samples from the Oral Psoriatic Arthritis TriaL [OPAL], to identify biomarkers of treatment response). GRAPPA-CRN funding partnerships and applications are also underway with both the Innovative Medicines Initiative (IMI) in Europe and Accelerating Medicines Partnerships (AMP) 2.0 in the USA, and the progress of these applications and associated objectives were presented.
在 2020 年银屑病和银屑病关节炎研究和评估小组 (GRAPPA)-合作研究网络 (CRN) 年会上，GRAPPA-CRN 小组提出了一项试点研究者发起的研究方案，以测试电子病例报告表 (eCRF)，并提出了评估与轴性疾病相关的银屑病关节炎 (PsA) 生物标志物的标准化操作程序 (SOP)。还介绍了 3 项研究的进展：BioDAM PsA（生物标志物作为预测 PsA 结构损害的指标；验证可溶性生物标志物作为预测 PsA 结构损害的指标）、PreventPsA（检查银屑病患者和无关节炎患者中 PsA 的发展和危险因素）和 PredictORPsA（预测早期 PsA 患者的治疗反应；与辉瑞合作，使用来自口腔银屑病关节炎试验 [OPAL] 的样本，以确定治疗反应的生物标志物）。GRAPPA-CRN 的资助伙伴关系和申请也正在与欧洲的创新药物倡议 (IMI) 和美国的加速药物合作关系 (AMP) 2.0 进行，并介绍了这些申请和相关目标的进展。
